Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Recruiting
1
100.0%
No approval data available
- Anocca AB raised SEK 440 million ($46 million) in financing led by Mellby Gård to advance VIDAR-1, Europe's first non-viral gene-edited TCR-T cell therapy targeting pancreatic cancer. - The Phase I multi-center trial is now recruiting patients across eight sites in Sweden, Denmark, Germany, and The Netherlands, targeting mutant KRAS in pancreatic ductal adenocarcinoma. - VIDAR-1 represents a breakthrough approach for pancreatic cancer patients, who face a five-year survival rate of less than 10% with limited definitive treatment options currently available. - The funding will support early-stage clinical development of VIDAR-1 and advance Anocca's preclinical pipeline of TCR-T therapies for solid tumors and other difficult-to-treat diseases.
- MaxCyte has signed a Strategic Platform License Agreement with Anocca AB to support the scalable development and manufacturing of TCR-T cell therapies using Flow Electroporation technology. - Anocca will deploy MaxCyte's ExPERT platform for non-viral gene editing workflows across its therapeutic pipeline, including a lead program targeting mutant KRAS-driven advanced pancreatic cancer. - The partnership provides Anocca with non-exclusive research, clinical and commercial rights to MaxCyte's technology platform, while MaxCyte receives annual licensing fees and program-related revenue. - Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators for its cell therapy production facility.
